Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Abstract

While nivolumab improves overall survival, at its current cost it would not be considered a cost-effective treatment option for patients with HNC.